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A composite glandular/exocrine-endocrine carcinoma of the gastrointestinal tract is characterized by the co-existence of two adjacent, 
but histologically-distinct tumors in an organ. Composite glandular/exocrine-endocrine carcinomas are a special type of tumor comprised 
of common adenocarcinomas and neuroendocrine components that account for at least one-third of the entire tumor area. Composite 
tumors have been reported in a range of organs, but are relatively rare in the stomach. We report a case of a composite neuroendocrine 
carcinoma with an adenocarcinoma of the stomach (mixed exocrine-endocrine carcinoma), which was misdiagnosed as a giant submu-
cosal tumor preoperatively based on esophagogastroduodenoscopy and a contrast-enhanced axial computed tomographic scan.
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Introduction
Human cancers exhibiting a combination of conventional (glan-
dular, squamous, or urothelial) and neuroendocrine features occur 
in various organs. Such lesions are classified into two subgroups: 
composite and collision-type tumors.(1,2) Composite neuroendo-
crine carcinomas with adenocarcinomas occur throughout the gas-
trointestinal tract, but rarely occur in the stomach.(3) The histogen-
esis of composite tumors is unclear, but both types of carcinomas 
may be derived from the same cell, most likely a pluripotent stem 
cell. Composite neuroendocrine carcinomas with adenocarcinoma 
in the stomach can be diagnosed if neuroendocrine marker shows 
a positive reaction in the immunohistochemical staining of the 
component of the neuroendocrine carcinoma.(4)
W e report a case of a composite neuroendocrine carcinoma 
with adenocarcinoma of the stomach (mixed exocrine-endocrine 
carcinoma), which was misdiagnosed as a giant gastric submucosal 
tumor preoperatively by esophagogastroduodenoscopy (EGD) and 
contrast-enhanced axial computed tomographic (CT) scan. By 
immunohistochemical staining of the neuroendocrine carcinoma 
component, the tumor was identified as a composite neuroendo-
crine carcinoma with adenocarcinoma of the stomach. W e report 
this rare case with a review of the literature.
Case Report
A 62-year-old woman underwent EGD, abdominal CT and 
abdominal ultrasonography as part of an evaluation for epigastric 
discomfort. Her past medical and family histories were unremark-
able. The physical examination on admission, routine blood tests, 
and urine analysis were also unremarkable. The levels of tumor 
markers were within the reference range, as follows: carcinoem-
bryonic antigen (CEA), 5.21 ng/ml (normal, ≤8 ng/ml); CA 19-
9, 10.49 U/ml (normal, ≤37 U/ml); and CA 72-4, 0.289 ng/ml 
(normal, ≤6.9 ng/ml).
The EGD revealed a huge, well-defined, fungating, submuco-
sal mass with eccentric ulceration characterized by an ill-defined 
margin in lesser curvature of the gastric antrum (Fig. 1). An EGD 
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biopsy was not performed because a biopsy is not generally recom-
mended for the diagnosis of gastric submucosal tumors. A contrast-
enhanced axial CT scan demonstrated a huge, solid, ovoid, hetero-
geneous, exophytic mass measuring approximately 15×10 cm in 
the pre-pyloric antrum of the stomach with several metastasis into 
the lymphatic glands around the stomach was observed (Fig. 2). A 
diagnosis of a giant submucosal tumor of the stomach with lymph 
node metastasis was made, and a radical subtotal gastrectomy with 
D2 lymph node dissection was subsequently performed. 
Grossly, a diffuse submucosal bulging mass was noted in the 
surgically-resected stomach. The mass-measure 17×15×6.5 cm, 
and had an intact mucosa, with the exception of a small polypoid 
nodule with a central ulcerated umbilication measuring 1.5×1 cm. 
On sectioning, the cut surface of the mass showed a diffuse, geo-
graphic, hemorrhagic, necrotic area with a cleft-like cystic change 
and grayish-brown solid area which infiltrated to the surrounding 
omental fat tissue.
Microscopically, the tumor was comprised of a conventional 
adenocarcinoma with anaplastic glandular nests and a neuroen-
docrine carcinoma with central necrosis (Fig. 3). The glandular 
carcinoma was confined to the mucosa and submucosa, the neuro-
endocrine carcinoma had invaded into the serosa and the lymphatic 
glands. Two of 39 lymph nodes had metastases, and lymphatic and 
perineural invasion were observed. Immunohistochemically, the 
tumor cells exhibited immunopositivity for chromogranin A and 
synaptophysin, but negativity for CD56, CD117, CD34, and SMA. 
The neuroendocrine carcinoma components showed strong immu-
nopositivity for chromogranin A, but were negative for the adeno-
carcinoma component (Fig. 4). 
The post-operative course was uneventful and the patient was 
discharged on the 9th postoperative day.
Discussion
Submucosal tumors refer to tumors that exist below the mucosal 
layer and protrude into the lumen in a hemispherical or spherical 
Fig. 2. Preoperative contrast-enhanced axial CT scan shows a huge, solid, ovoid, heterogenous and exophytic mass measuring approximately 15×10 
cm in the prepyloric antrum of the stomach.
Fig. 1. Gastroduodenoscopy shows a 
huge, well-defined fungating submuco-
sal mass, measuring 10 cm in its largest 
dimension with eccentric ulceration 
and an ill-defined margin in the gastric 
antrum, lesser curvature.Kim TY and Chae HD
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shape because of the surrounding mucosa on the surface.
Submucosal tumors can cause symptoms, such as bleeding, but 
in most cases, submucosal tumors are detected incidentally dur-
ing gastroduodenscopy or an upper GI series. On routine EGD, 
the rate of diagnosing submucosal tumors is approximately 0.36%. 
(5) Submucosal tumors that usually occur in the stomach include 
gastrointestinal stromal tumors (GISTs), leiomyomas, leiomyo-
sarcomas, lipomas, and carcinoids. However, the gastric cancers 
with a pattern of submucosal tumors are very rare, accounting for 
0.1~0.62% of resected gastric cancers.(5,6) The pathologic diagnosis 
of most gastric cancers is an adenocarcinoma. In our case, a giant 
protruding lesion covered with gastric mucosa was noted during 
the pre-operative EGD, and the origin of the tumor was located 
in the submucosal muscularis propria layer, as demonstrated by a 
contrast-enhanced axial CT scan. Therefore, we diagnosed the tu-
mor clinically as a malignant gastric GIST and performed a radical 
subtotal gastrectomy. 
Composite glandular/exocrine-endocrine carcinomas of the 
gastrointestinal tract are special tumors comprised of common ad-
enocarcinomas with neuroendocrine components, and accounts for 
at least one-third of the entire tumor area. Glandular-endocrine 
tumors of the digestive tract have rarely been described in the 
medical literature because the classification, which restricts the 
term “mixed” to lesions in which the endocrine cells account for 
between about one-third and one-half of all cells, and proposed a 
classification for such neoplasms distinguishing (a) composite (or 
mixed) glandular-endocrine tumors with both elements in more or 
less equal proportions, (b) amphicrine tumors with dual differentia-
tion within the same cell, and (c) collision tumors in which the two 
components are juxtaposed, but not admixed.(6) According to this 
classification, the case herein was a composite glandular-endocrine 
carcinoma. 
More recently, Fujiyoshi et al.(7) reclassified mixed endo-
crine and non-endocrine epithelial tumors by dividing the tu-
mors into six categories: 1) neuroendocrine cells interspersed 
within carcinomas; 2) carcinoids (neuroendocrine tumors [NETs]) 
with interspersed non-endocrine cells; 3) composite glandular-
neuroendocrine cell carcinomas containing areas of carcinoid and 
conventional carcinomas; 4) collision tumors in which NETs and 
conventional carcinomas are closely juxtaposed, but not admixed; 
5) amphicrine tumors predominantly composed of cells exhibit-
ing concurrent neuroendocrine and non-endocrine differentiation; 
and 6) combinations of the previous types. According to this clas-
sification, our case could be classified as a composite glandular-
endocrine carcinoma containing mainly a NET with small areas of 
a conventional carcinoma.
Composite neuroendocrine carcinomas with adenocarcinomas 
in the stomach can be diagnosed if at least one of the neuroendo-
crine markers, such as chromogranin A, synaptophysin, and NSE 
has a positive reaction in the immunohistochemical staining of the 
neuroendocrine carcinoma component.(4) In the case herein, the 
component of the neuroendocrine carcinoma had a strong positive 
response to chromogranin A, which is a neuroendocrine marker, 
but the adenocarcinoma component was negative (Fig. 4).
With the exception of the appendix, only rare instances of 
composite tumors have been detected in the esophagus, stomach, 
Fig. 3. The tumor is composed of conventional adenocarcinoma with 
anaplastic glandular nests (arrow) and neuroendocrine carcinoma with 
central necrosis (arrow head) (H&E, ×100).
Fig. 4. Neuroendocrine carcinoma com  ponents show strong immu-
nopositivity for chromogranin A (left upper), but negative immunos-
taining of adenocarcinoma component (right lower) (Immunohisto-
chemical stain, ×200).Composite Tumor of the Stomach
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gallbladder, and the small and large bowel. However, it is possible 
that before the advent of immunohistochemistry, the true incidence 
of composite tumors was underestimated. 
The histologic origin of composite tumors is unclear. In rats 
with hypergastrinemia, enterochromaffin-like cells have the ca-
pacity to dedifferentiate and become potential precursors of gastric 
adenocarcinomas.(8,9) Some authors have postulated proliferation 
of a pluripotential precursor cell,(10-12) and studies describing 
common genetic alterations in the glandular and neuroendocrine 
component of mixed tumors support the latter hypothesis.(12)
Because of their rarity and uncertain pathologic criteria, the 
clinical behavior and histogenesis of composite tumors is still 
unclear, but V olante et al.(13) reported that the clinical behavior 
of composite carcinomas depends on the adenocarcinomatous 
component if the associated endocrine component is well-differ-
entiated, and upon the neuroendocrine component if it is poorly-
differentiated. In this case, although the glandular carcinoma was 
confined to the mucosa and submucosa, the neuroendocrine carci-
noma had invaded into the serosa and the lymphatic glands. There-
fore, the neuroendocrine component of this case was believed to 
impact heavily on the prognosis and we performed chemotherapy 
based on the neuroendocrine carcinoma. 
Treatment of neuroendocrine cancers that occur in the stomach 
is based on radical surgical resection. In cases of distant metastasis, 
such as liver metastasis, a gastrectomy with hepatectomy is effec-
tive treatment.(14) Chemotherapeutic regimens, including cisplatin, 
doxorubicin, and vincristine can be administered to neuroendocrine 
carcinoma patients. Because combination treatment of cisplatin and 
etoposide after gastrectomy has been reported to result in reduction 
of liver metastasis by 96% and lung metastasis by 81%, chemother-
apy has recently been recommended to be administered following 
gastrectomy; however, the efficacy has not been fully verified due 
to the low incidence.(15)
In summary, we initially misdiagnosed the tumor as a giant 
gastric submucosal tumor by EGD and contrast-enhanced axial CT 
scan, and subsequently performed surgical resection. However, in 
retrospect, metastasis into the lymphatic glands around the stomach 
was observed in the pre-operative contrast-enhanced axial CT 
scan, and eccentric ulceration with an ill-defined margin was noted 
on EGD, which could have been diagnosed as metastasis into the 
lymphatic glands around the stomach secondary to gastric cancer. 
Therefore, if a submucosal tumor is large and eccentric ulceration 
with ill-defined margins is observed with lymphatic gland metas-
tasis around the stomach, an adenocarcinoma, and although ex-
tremely rare, a composite glandular-endocrine carcinoma contain-
ing a conventional carcinoma should be taken into consideration in 
the differential diagnosis.
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